Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis: Fifty‐Two–Week Phase III Randomized Study Results

OBJECTIVE: The 24‐week equivalent efficacy and comparable safety results of the biosimilar SB5 and reference adalimumab (ADA) from the phase III randomized study in patients with moderate‐to‐severe rheumatoid arthritis (RA) have been reported previously. We undertook this transition study to evaluat...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Arthritis Rheumatol
Main Authors: Weinblatt, Michael E., Baranauskaite, Asta, Dokoupilova, Eva, Zielinska, Agnieszka, Jaworski, Janusz, Racewicz, Artur, Pileckyte, Margarita, Jedrychowicz‐Rosiak, Krystyna, Baek, Inyoung, Ghil, Jeehoon
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2018
Assuntos:
Rheumatoid Arthritis
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6001519/
https://ncbi.nlm.nih.gov/pubmed/29439289
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/art.40444
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados